Why the study?
Does very late rejection (VLR) increase the risk of cardiac allograft vasculopathy progression in clinically stable heart transplant recipients?
Population
196 clinically stable heart transplant recipients with >7-year follow-up (out of 398 consecutive recipients)
Comparison
Very late rejection vs Matched control group of patients without…
Design
Cohort
Follow-up
6.4 ± 1 years post-reference EMB
Authors
Loading...
Supports enhanced CAV surveillance after VLR; leaves open whether targeted interventions alter progression or survival in heart transplant recipients.
Does very late rejection (VLR) increase the risk of cardiac allograft vasculopathy progression in clinically stable heart transplant recipients?
Very late rejection in heart transplant recipients is frequently associated with antibody-mediated microvascular injury and leads to severe progression of cardiac allograft vasculopathy.
Loupy et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: